Responses
Immune cell therapies and immune cell engineering
Original research
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.